Phinomics

Executive Summary

Phinomics is a precision oncology biotechnology company developing a proprietary 'Cancer Intelligence Platform' that decodes extrachromosomal circular DNA (ecDNA) and cryptic micro-proteins—previously hidden drivers of cancer progression, evolution, and drug resistance. By integrating these missing biological signals with multi-modal data, the platform aims to identify novel, previously undruggable targets and predictive biomarkers. Founded in 2015 and headquartered in San Diego, Phinomics operates at the forefront of RNA and gene therapy, addressing critical gaps in understanding how tumors evade treatment. The company's approach leverages recent advances in genomics and proteomics to uncover the role of ecDNA in amplifying oncogenes and generating tumor heterogeneity, which is a major contributor to therapy failure. Cryptic micro-proteins, often overlooked due to their small size, are increasingly recognized as key modulators of cancer cell signaling. Phinomics' platform holds promise for developing first-in-class therapeutics and companion diagnostics that could significantly improve patient outcomes. Despite its innovative science, Phinomics remains at an early stage with no disclosed funding, partnerships, or clinical pipeline. The company is privately held and has limited public visibility. The success of its platform hinges on experimental validation of its target identification capabilities and subsequent progression toward preclinical development. Key risks include the technical challenges of targeting ecDNA and micro-proteins, as well as the competitive landscape of oncology discovery platforms. However, if the platform can demonstrate robust target identification and validation, Phinomics could attract strategic partnerships or funding to advance its programs. The next 12-24 months will be critical for the company to achieve proof-of-concept milestones and establish its position in the rapidly evolving field of ecDNA-targeted cancer therapy.

Upcoming Catalysts (preview)

• Q4 2025Publication of ecDNA target identification data in peer-reviewed journal60% success
• Q2 2026Securing Series A funding or strategic partnership40% success
• Q1 2026Announcement of lead candidate nomination for preclinical development35% success